on NANOBIOTIX (EPA:NANO)
NANOBIOTIX Responds to Media Speculation on Takeover Intentions
On March 25, 2026, NANOBIOTIX, a biotechnology firm focused on nanotherapeutic approaches, addressed recent media rumors about a potential public takeover. According to the company, there are no plans or ongoing processes regarding such an acquisition. The company also noted inaccuracies in the media report, which contradict their latest public disclosures.
Nanobiotix, listed on Euronext and NASDAQ, emphasized that, to its knowledge, no takeover intentions exist. It remains focused on its ongoing projects and the potential expansion of treatment options for cancer and other diseases using their proprietary nanotechnology platforms.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all NANOBIOTIX news